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Abstract
Objective—Quantify the impact of diabetes status on healthy and disabled years of life for older 
adults in the U.S. and provide a baseline from which to evaluate ongoing national public health 
efforts to prevent and control diabetes and disability.
Research Design and Methods—20,008 adults aged 50 years and older followed from 1998 
to 2012 in the Health and Retirement Study, a prospective biannual survey of a nationally 
representative sample adults. Diabetes and disability status (defined by mobility loss, difficulty 
with instrumental activities [IADL], and/or difficulty with activities of daily living [ADL]) were 
self-reported. We estimated incidence of disability, remission to non-disability, and mortality. We 
developed a discrete-time Markov simulation model with a 1-year transition cycle to predict and 
compare lifetime disability-related outcomes between persons with and without diabetes. Data 
represent the U.S. population in 1998.
Results—From age 50, diabetic adults died 4.6 years earlier, developed disability six to seven 
years earlier and spent about one to two more years in a disabled state than non-diabetic adults. 
With increasing baseline age, diabetes was associated with significant (p<0.05) reductions in the 
number of total and disability-free life years, but the absolute difference in years between those 
with and without diabetes was less than at younger baseline age. Diabetic men spent about twice 
as much of their remaining years disabled (20% to 24% of remaining life across the 3 disability 
definitions) as men without diabetes (12% to 16% of remaining life across the 3 disability 
definitions). Similar associations between diabetes status and disability-free and disabled years 
were observed among women.
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Conclusions—Diabetes is associated with a substantial reduction in non-disabled years, to a 
greater extent than the reduction of longevity.
INTRODUCTION
Diabetes is one of the most common public health threats in the U.S., affecting 12% of 
adults and carrying an estimated lifetime probability of 40%(1; 2). Furthermore, increases in 
life expectancy of the diabetes population have led to a large increase in the number of years 
spent with diabetes for the average person(1). This, combined with increased prevalence 
since 1985, has led to a 156% and 70% increase in the number of years that a typical 
community of men and women, respectively, will spend with diabetes(1).
Diabetes is known for its diverse vascular and neuropathic complications and for the 
associated excess risk of disability. Disability experienced among people with diabetes 
includes loss of mobility, and the ability to carry out instrumental and basic activities of 
daily living(3–6). The increased risk of disability erodes quality of life, increases morbidity, 
and increases the need for health services and social security resources, relative to non-
diabetic peers(7). Disability-free life-years is a measure of population health that quantifies 
the impact of health conditions on non-disabled and disabled years(8). As such, it provides 
an important metric to gauge the impact of chronic conditions, as well as attempts of public 
health interventions to compress morbidity in the population alongside reductions in 
mortality.
Despite the well documented impact of diabetes on diverse forms of macrovascular 
morbidity(9) and mortality(10), there have been no national estimates of the years of 
disability-free versus disabled life years lost to the disease among U.S. adults. In these 
analyses, we assembled prospective cohort data on incidence of disability and mortality 
among a diverse, population-based sample of U.S. adults aged ≥50 years to quantify the 
impact of diabetes on disability-free and disabled years of life and to provide a baseline from 
which to evaluate the impact of national public health efforts to control and prevent diabetes.
METHODS
Population and data sources
Our analyses are based on 20,008 adults aged 50 and older enrolled in the Health and 
Retirement Study (HRS), a population based longitudinal cohort study(11). Respondents 
entered in 1998 with biennial visits in 2000, 2002, 2004, 2006, 2008, 2010, and 2012. Initial 
response rates ranged from 69 to 81%, and follow-up response rates were 87 to 89%(12). 
Reports from the 8 visits, described below, were used to estimate prevalence and incidence 
of diabetes, incidence of disability, mortality, and incidence transitions from diabetes and 
non-diabetes status to disability and mortality, as well as remission from disability to non-
disabled states and mortality. The HRS is sponsored by the National Institute on Aging and 
performed by the Institute for Social Research at the University of Michigan. The Health 
Sciences Institutional Review Board at the University of Michigan approved the HRS study 
design. The data used for this analysis were stripped of unique personal identifiers and are 
publicly available. The data used for our analyses are nationally representative.
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Definitions
Prevalent diabetes was defined by the survey question of whether the individual had been 
diagnosed by a physician with diabetes or high blood glucose. Incident diabetes was defined 
as the first self-report by a respondent to HRS of a diabetes diagnosis (i.e., being told by a 
doctor that he or she has diabetes or high blood sugar) during the study period(13). Incident 
diabetes cases were incorporated into analyses such that an individual who was diagnosed 
with diabetes after baseline was included in the diabetes group only if they did not become 
disabled prior to a diabetes diagnosis. If they became disabled after they were diagnosed 
with diabetes they were considered an incident case of disability in the diabetes group.
Mobility disability was defined as self-report of difficulty with any of the following: walking 
one block; climbing one flight of stairs; stooping, crouching, or kneeling; pushing or pulling 
a large object(14). Modifying a previously developed four state model for defining mobility 
disability among persons with diabetes(14), we classified a respondent’s mobility disability 
as severe if they reported four or five of the previously mentioned mobility measures. 
Similarly, instrumental activities of daily living (IADL) were defined as self-report of 
difficulty doing any of the following: using the telephone, taking medication, handling 
money, shopping, and preparing meals. Activities of daily living (ADL) were defined as self-
report of difficulty doing any of the following: walking across a room, getting in and out of 
bed, dressing, bathing, and eating. Death was determined during exit interviews with the 
respondent’s proxy, family or friend, and confirmed as valid by the National Center for 
Health Statistics via linkage to the National Death Index (12). The year of death reported 
during the exit interview was used for censoring at time of death. If year was unknown, year 
of exit interview was used (n=126, 7%).
Estimation of Incidence
Age-specific incidence of mobility, ADL, and IADL were modeled using generalized 
estimating equations with a binary outcome, wherein persons with prevalent disability at 
baseline were excluded. All the regression models were stratified by sex and included age, 
piecewise age function, and diabetes status. Data were modeled with STATA version 13 
(StataCorp, College Station, Texas) which accounts for the longitudinal complex survey 
design. Estimates were weighted to the U.S. population in 1998, followed through 2012. 
Regression estimates were used to determine the probability of incident disability among 
those with and without diabetes by age. We were unable to further stratify on race/ethnicity 
due to the small sample size. Therefore we adjusted for race/ethnicity by centering 
individual responses around the grand mean. Thus, our primary findings are adjusted for the 
proportion of respondents by race/ethnicity. We conducted additional analyses adjusting for 
the prevalence CVD to determine its effects on the primary outcomes (incidence, remission, 
and mortality) affecting healthy life years. These probabilities were used as inputs to the 
Markov models. Similarly, probability of remission from disability was calculated on a 
yearly basis as the persons with incident disability (for mobility, IADL, and/or ADL, 
respectively) who return to a state of non-disablement.
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Modeling Approach
We developed a discrete-time Markov cohort simulation model with annual transition to 
predict and compare lifetime disability-related outcomes between persons with and without 
diabetes from age 50 through 100. (15) (Figure 1). The model has five states: not disabled, 
short-term disability, not disabled but with previous disability, permanent disability, and 
death. Each year, the specific proportion that moves between states (i.e., transition 
probabilities) was determined by the regression models.
We created states of short-term disability and not being disabled but with disability history 
(i.e., recovered from disability) as two bridge states (i.e., connections between states) 
because of the high remission rates (returning to non-disabled states) observed in the data. 
Moreover, to simplify the model, the state of short-term disability is defined as being 
disability and having no remission by the end of the first year of disability onset. Therefore 
in the model, a person with disability onset will either recover or move to the state of 
permanent disability in the next year. The assumption is supported by the fact that few 
remissions occurred later in the study. Further, like those in the study population, individuals 
may have multiple episodes of short-term disability over their lifetime in the model.
On the basis of the model, we predicted 3 disability-related outcomes including the 
remaining lifetime risk of becoming disabled, average age of disability onset, and remaining 
life-years living with and without disability, among adults who reported having and not 
having diabetes at ages 50, 60, 70 and 80. Remaining lifetime risk was calculated as the 
cumulative risk of experiencing short-term or permanent disability over a lifetime. Because 
of the high frequency of multiple episodes of short-term disability, the average age of onset 
was defined as the difference between the life expectancy and mean disability-free life years. 
For example, from a baseline age of 50, it is possible to become disabled at age 56, recover 
at 58 and then become disabled again at age 64. Therefore the average age of onset was 
defined by taking the difference between life expectancy from age 50, and the average 
number of disability-free life years remaining instead of choosing the age of onset of one of 
the disabled episodes. The confidence intervals and p-values of the lifetime estimates were 
estimated using a Monte Carlo simulation of the Markov model with transition probabilities 
sampled from the previously described regression models. Five thousand runs were 
performed for each group with or without diabetes.
RESULTS
Study Population Characteristics
Among the 20,008 respondents in the analytic sample, age ranged from 50 to 105, and 
baseline diabetes prevalence was 14.1% among men and 12.2% among women. Among both 
genders, about 15%-17% of the population was non-white and 22%-23% was obese. (Table 
1) Among those with a diabetes diagnosis at baseline, 8.7% were taking insulin and oral 
medication, 52.4% were taking oral medication only, 17.1% were taking insulin only, and 
21.7% were taking no antidiabetic medications. The vast majority of all respondents who 
reported they had high blood pressure at baseline reported they were taking medication for 
high blood pressure (those with diabetes: 87%; those without diabetes 81%).
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Incidence of Diabetes, Disability and Mortality
Estimated incidence of diabetes was 1.5% per year among men and 1.3% per year among 
women. Annual incidence of severe mobility disability increased with age from absolute 
levels of 0.4% in men and 0.6% in women at age 50, roughly doubling in incidence by age 
60, quadrupling by age 68, and then increased 20 times by age 87. (Data not shown) 
Compared to severe mobility disability, incidence of IADL and ADL disability increased 
similarly from age 50 to 68 and increased 26 times for women and 27 times for men by age 
87. Among both men and women, disability rates (mobility, IADL, ADL) were 1.5 to 2 
times higher among persons with diabetes. Disability rates were 27 to 35% higher among 
diabetic women than diabetic men; sex-related differences in disability were smaller among 
those without diabetes.
Incidence of remission from disability was more than 20% per year for most strata, (Table 2) 
was greater for those without diabetes than for those with diabetes, and declined 
substantially with age in all groups. (Data not shown, p <0.001) Mortality rates among those 
with diabetes were about twice as high as their non-diabetic counterparts, but the relative 
risk of mortality associated with diabetes decreased with increasing age. (Data not shown) 
Additional analyses adjusting for prevalent CVD at baseline resulted in less than 0.3 
percentage point difference from the estimates unadjusted for prevalent CVD. (Appendix, 
Table 2a)
Disability-Free and Disabled Life Years
Across all ages and disability definitions, having diabetes was significantly associated with 
reduced years of total life and reduced disability-free life years compared to persons without 
diabetes. (Tables 3 and 4). However, there was a greater impact of diabetes on disability-free 
life years than on total life years, and those with diabetes spent a greater proportion of their 
remaining years in a disabled state, particularly among those incident at younger ages. This 
is illustrated in figures 2a and 2b for mobility loss disability; results were similar for ADL 
and IADL disability (Data not shown). From age 50, diabetic men died 4.6 years earlier, 
developed disability six years earlier, and spent one to one and a half more years in a 
disabled state than non-diabetic men. This means that diabetic men spent about twice as 
much of their remaining years disabled (20% to 24% of remaining life across the three 
disability definitions) compared to men without diabetes (12% to 16% of remaining life 
across the three disability definitions). With increasing baseline age, diabetes was still 
associated with significant reductions in the number of total and disability-free life years, but 
the absolute difference in years lost between those with and without diabetes was less than at 
younger baseline age; the exceptions to this were that by ages 60, 70, and 80, IADL disabled 
years were no longer significantly different between groups and by ages 70 and 80, the 
difference in ADL disabled years between people with and without diabetes was no longer 
significant.
Similar associations between diabetes status and disability-free and disabled years were 
observed among women. From age 50, diabetic women had an average disability onset six to 
seven years earlier than non-diabetic women and lived one to two years longer in a disabled 
state. The largest difference was observed for mobility disability, where diabetic women 
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from age 50 lost seven disability-free years and had 2.5 more disabled years compared to 
non-diabetic women. Also similar to men, women with diabetes spent about one and a half 
times as much of their remaining years disabled (27% to 32% across the 3 disability 
definitions) as women without diabetes (20%-22% across the 3 disability definitions). 
Similar to men, the diabetic vs non-diabetic differences in disability among women were 
significant and decreased with increasing age; the exceptions to this were that by ages 70 
and 80, differences in IADL disabled years between all diabetic and non-diabetic adults 
were no longer significant, and by ages 70 and 80, the difference in ADL disabled years was 
no longer significant.
DISCUSSION
Using a large, nationally representative cohort of Americans aged 50 years and older, we 
found that diabetes is associated with a substantial deterioration of non-disabled years and 
this is a greater number of years than on the loss of longevity associated with diabetes. On 
average, a middle-aged adult with diabetes has an onset of disability six to seven years 
earlier than one without diabetes, spends one to two more years with disability, and loses 
seven years of disability-free life to the condition. Although other nationally-representative 
studies have reported large reductions in complications9 and mortality among the diabetic 
population in recent decades1, these studies, akin to our results, suggest that diabetes 
continues to have a substantial impact on morbidity and quality of remaining years of life.
The differences in disability-free and disabled life years between persons with and without 
diabetes were driven by several factors. First, persons with diabetes had considerably higher 
disability incidence at all ages, leading to a younger age of disability onset and more years 
spent in a disabled state. Second, once a diabetic person became disabled, they were less 
likely to revert to regular functioning, therein increasing the number of years with disability. 
Third, diabetes and disability were each associated with increased mortality, which has a 
modest contradictory effect on the first two factors (i.e., incidence and remission of 
disability), as the increased mortality reduces the number of years spent in both a healthy 
and unhealthy state. Given this combination of factors, improving the number of disability-
free life years over time will depend upon identification of interventions that can reduce 
disability and increase remission at least as much as mortality rates are being reduced.
The association of diabetes with disability has been found to be multifactorial(4; 16; 17). 
Previous studies have suggested that coronary heart disease, lower extremity arterial disease, 
and obesity explain a particularly large proportion of the difference in disability between 
persons with and without diabetes(4; 16; 18). However, these factors are likely to vary by 
gender, and numerous other factors, including physical inactivity, inflammatory factors, 
insulin resistance, and diabetes-related complications (such as neuropathy, kidney disease, 
stroke, hyperglycemia and hypoglycemia) may intervene. Our findings related to mortality 
are also consistent with national estimates that among older adults, diabetes is associated 
with 60-70% increases in mortality rates and 4.6-5.7 years of reduced lifespans(1). We are 
not aware of previous estimates of the rate of remission from disability, and it is noteworthy 
that people with diabetes were less likely to recover from disability, which could also be an 
indication that their levels of disability were somewhat more severe(19). Several recent 
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developments in the epidemiology of diabetes complications from intervention studies have 
made disability-free and disabled years increasingly important metrics for assessing the 
impact of diabetes. While rates of complications have declined, the extra years of life spent 
with diabetes and cumulative morbidity that follows could erode the quality of those extra 
years of life. Also, older adults are the fastest growing segment of the diabetic population, 
raising the importance of physical disability and other geriatric syndromes that may result 
from or be associated with diabetes(20).
In addition, and perhaps most importantly, there is increasing evidence that disability is 
modifiable with lifestyle interventions(14; 21). The Look AHEAD Study found that 
intensive lifestyle intervention results in a 50% reduced incidence of physical disability 
among adults with diabetes(14). Similarly, the general effectiveness of similar interventions 
among older and overweight adults with osteoarthritis have found that structured exercise 
and moderate weight loss programs can improve functional status(22). In theory, many other 
aspects of risk factor modification initiated through primary care, including glycemic and 
blood pressure control, could also affect disability risk, but there has been little evaluation of 
the effects of such interventions on disability. We did not adjust for other risk factors for 
morbidity and mortality, such as hypertension, obesity, CHD and stroke, which were largely 
unbalanced among people with and without diabetes at baseline so that we could determine 
the overall differences in remaining disability life years and disability-free life years 
between those with and without diabetes. However, incidence of disability, remission from 
disability, and mortality changed only slightly when adjusting for prevalent CVD. Assessing 
the contribution of the specific related reason for the differences is warranted.
There are several limitations to this study. First, diabetes was based on self-report, which 
means that persons with undiagnosed diabetes were classified as non-diabetic; if their 
disability risk is higher than true non-diabetic adults, the difference in disability-free life 
years between diabetic and non-diabetic adults in our analyses would be underestimated. 
Our disability estimates are also based on subjective reports, for which interpretation and 
agreement with objective measurements could vary by diabetes status. Third, we could not 
distinguish between secondary diagnosis of diabetes and primary diagnosis due to the self-
reporting of the diagnosis. Fourth, though the incident cases of diabetes were accounted for 
in the age-specific probabilities input into the Markov models, those models were designed 
to compare people with prevalent diabetes and those without prevalent diabetes who do not 
develop diabetes in their lifetime. Thus the final estimates should be interpreted with the 
assumption that diabetes status did not change at the specified age. Although the majority of 
persons without diabetes at age 70 will not develop diabetes, this ignores a substantial 
minority of persons who become incident diabetes cases after baseline. The group of people 
who go on to develop diabetes later are likely to have a number of disability-free and total 
years remaining that is intermediate between the groups with and without diabetes. Finally, 
our estimates did not adjust for potential intervening and confounding factors such as 
obesity, coronary heart disease, and lower extremity disease. However, the objective here 
was to quantify the basic differences in disability-free life years by diabetes status occurring 
in the U.S. population.
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Despite these limitations, these analyses are the first ever quantification of disability-free 
and disabled years experienced after age 50 for the U.S. diabetic population, which 
incorporates information on disability incidence, disability remission, and mortality across 
older ages. As such, these findings are an important baseline from which to monitor the 
success of future clinical and public health efforts to reduce diabetes and its complications as 
well as interventions aimed directly at reducing disability.
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Figure 1. 
The five states Markov model
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Figure 2a. 
Disability-free and mobility loss disability life years remaining by age for men with and 
without diabetes
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Figure 2b. 
Disability-free and mobility loss disability life years remaining by age for women with and 
without diabetes
Bardenheier et al. Page 12
Diabetes Care. Author manuscript; available in PMC 2018 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bardenheier et al. Page 13
Ta
bl
e 
1
G
en
er
al
 c
ha
ra
ct
er
ist
ic
s o
f s
tu
dy
 p
op
ul
at
io
n 
ac
co
rd
in
g 
to
 d
ia
be
te
s s
ta
tu
s a
t b
as
el
in
e.
M
en
W
o
m
en
D
ia
be
te
s
n
 (%
)
N
o 
D
ia
be
te
s
n
 (%
)
n
to
ta
l d
ea
th
s*
D
ia
be
te
s
n
 (%
)
N
o 
D
ia
be
te
s
n
 (%
)
n
to
ta
l d
ea
th
s*
A
ge
 5
0-
59
31
8 
(31
.8)
22
25
 (4
1.9
)
51
5
37
1 
(26
.5)
30
36
 (3
7.3
)
48
2
 
60
-6
9
50
4 
(31
.9)
25
62
 (2
8.0
)
10
98
53
7 
(30
.8)
30
81
 (2
6.6
)
94
4
 
70
-7
9
39
0 
(27
.2)
18
03
 (2
1.9
)
14
90
42
8 
(30
.0)
22
93
 (2
3.7
)
15
55
 
80
+
13
8 
(9.
1)
74
5 
(8.
2)
84
7
20
8 
(12
.7)
13
69
 (1
2.3
)
14
01
M
ea
n 
ag
e 
± 
SE
65
.8
 ±
 0
.4
63
.9
 ±
 0
.2
–
67
.5
 ±
 0
.3
65
.5
 ±
 0
.2
–
R
ac
e/
Et
hn
ic
ity
:
 
N
on
-H
isp
an
ic
 w
hi
te
s
95
0 
(79
.0)
58
48
 (8
6.6
)
30
56
90
3 
(70
.3)
76
52
 (8
5.6
)
33
22
H
isp
an
ic
s
13
7 
(9.
1)
50
9 
(5.
6)
27
3
18
8 
(9.
9)
65
0 
(5.
8)
27
4
N
on
-H
isp
an
ic
 b
la
ck
s
23
2 
(11
.9)
83
0 
(7.
8)
54
5
41
7 
(19
.8)
12
98
 (8
.6)
72
1
Ed
uc
at
io
n 
< 
H
S
47
3 
(30
.2)
19
70
 (2
2.7
)
14
75
68
6 
(40
.7)
25
88
 (2
3.5
)
17
39
 
H
S
62
6 
(48
.0)
34
80
 (4
8.5
)
17
76
69
6 
(47
.5)
54
51
 (5
6.9
)
21
48
 
>
H
S
25
1 
(21
.8)
18
85
 (2
8.8
)
69
9
16
2 
(11
.8)
17
40
 (1
9.6
)
49
5
B
M
I <
 2
5
30
8 
(22
.1)
24
07
 (3
1.8
)
15
17
37
3 
(25
.2)
43
95
 (4
6.6
)
20
99
 
25
 to
 <
 3
0
58
5 
(42
.7)
34
85
 (4
7.7
)
17
18
49
6 
(32
.2)
31
97
 (3
2.9
)
12
98
 
≥3
0
45
5 
(35
.2)
14
27
 (2
0.5
)
70
8
64
1 
(42
.6)
19
93
 (2
0.5
)
90
0
Pr
ev
al
en
t A
D
L
27
7 
(20
.6)
90
9 
(11
.1)
84
2
47
5 
(29
.0)
15
55
 (1
4.9
)
13
41
Pr
ev
al
en
t I
A
D
L
24
5 
(17
.5)
77
9 
(9.
6)
77
0
41
7 
(25
.5)
13
26
 (1
2.6
)
12
62
Pr
ev
al
en
t m
ob
ili
ty
 lo
ss
20
4 
(15
.2)
53
7 
(6.
4)
57
2
40
4 
(25
.5)
11
65
 (1
1.2
)
10
59
Ca
rd
io
v
as
cu
la
r d
ise
as
e
 
H
ig
h 
bl
oo
d 
pr
es
su
re
81
4 
(59
.7)
28
53
 (3
6.9
)
19
11
10
80
 (6
8.4
)
40
30
 (3
8.6
)
24
76
 
H
ea
rt 
di
se
as
e
48
5 
(34
.6)
16
18
 (2
0.1
)
14
05
48
5 
(31
.7)
15
12
 (1
4.6
)
13
12
 
St
ro
ke
16
8 
(12
.6)
47
1 
(5.
7)
49
4
18
1 
(11
.3)
54
6 
(5.
4)
54
7
A
rth
rit
is
74
3 
(53
.3)
32
83
 (4
1.4
)
20
77
10
84
 (6
9.0
)
55
94
 (5
4.6
)
29
20
Lu
ng
 D
ise
as
e
10
5 
(8.
2)
54
9 
(6.
6)
50
5
14
0 
(9.
2)
62
3 
(6.
0)
52
3
En
te
re
d 
N
ur
sin
g 
H
om
e 
af
te
r b
as
el
in
e
24
 (1
.8)
92
 (1
.2)
–
52
 (3
.2)
28
1 
(2.
9)
–
Diabetes Care. Author manuscript; available in PMC 2018 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bardenheier et al. Page 14
A
D
L:
 A
ct
iv
iti
es
 o
f d
ai
ly
 li
v
in
g
IA
D
L;
 In
str
um
en
ta
l a
ct
iv
iti
es
 o
f d
ai
ly
 li
v
in
g
*
D
ie
d 
pr
io
r t
o 
en
d 
of
 th
e 
stu
dy
N
ot
e:
 a
ll 
da
ta
 a
re
 se
lf-
re
po
rte
d,
 ex
ce
pt
 d
ea
th
 w
hi
ch
 is
 re
po
rte
d 
by
 p
ro
xy
,
 
fri
en
d 
or
 fa
m
ily
,
 
an
d 
co
nf
irm
ed
 w
ith
 th
e 
N
at
io
na
l D
ea
th
 In
de
x
.
‘
–
‘
 
in
di
ca
te
s c
el
l s
iz
e 
to
o 
sm
al
l t
o 
re
po
rt 
fo
r c
on
fid
en
tia
lit
y
Diabetes Care. Author manuscript; available in PMC 2018 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bardenheier et al. Page 15
Table 2
Incidence (annual % and 95% confidence interval) of major sources of morbidity affecting disability-free life 
years among U.S. men and women with and without diabetes.
Men Women
Diabetes No Diabetes Diabetes No Diabetes
Disability Incidence
 Severe Mobility loss 3.3** (3.0, 3.6) 1.7 (1.6, 1.8) 5.0** (4.6, 5.4) 2.6 (2.4, 2.7)
 IADL 3.5** (3.2, 3.8) 2.2 (2.1, 2.4) 4.9** (4.6, 5.3) 2.7 (2.5, 2.8)
 ADL 3.8** (3.5, 4.1) 2.3 (2.2, 2.4) 5.1** (4.8, 5.5) 2.9 (2.8, 3.0)
Mortality Rate 4.1** (3.8, 4.4) 2.8 (2.7, 2.9) 4.0** (3.8, 4.3) 2.4 (2.3, 2.5)
Disability Remission*
 Severe Mobility loss 19.7** (17.6, 21.9) 23.4 (21.7, 25.1) 19.2 (17.3, 20.8) 20.9 (19.8, 22.0)
 IADL 22.1 (20.2, 24.0) 23.5 (22.3, 24.8) 16.7** (15.1, 18.2) 18.3 (17.0, 19.5)
 ADL 22.0** (20.3, 23.7) 25.3 (23.9, 26.6) 18.6** (17.3, 19.9) 22.4 (21.3, 23.5)
*
Estimated among persons with incident disability
**p-value <0.001 between those with and without diabetes within sex
ADL: Activities of daily living
IADL: Instrumental activities of daily living
Note: all models were adjusted for age, race/ethnicity and sex
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